N 3 (181) 2022. P. 13–16

HYDROSIN’S OXIDATION OF GIDAZEPAM FRAGMENT– ITS LIMITING ELIMINATION STAGE

G. F. Stepanov, K. V. Oleynik, A. A. Kostina, G. S. Maryniuk

Odessa National Medical University

DOI 10.32782/2226-2008-2022-3-2

The carried-out researches showed that administration by an animal of phenobarbital and omeprasol as a whole doesn’t influence on kinetics removal of radioactive material from organism of rats. In all cases the maximum removal of radioactive material in the first days is observed. Nevertheless, phenobarbital accelerates the excretion of substances by the renal way, and omeprasol – by biliar.

Considering the fact that phenobarbital is belong to the inductors CYP3А4, and omeprasol inhibitors substrate of CYP2С19 can assume that N1-dealkilation of gidazepam is catalyzed by these enzymes. Thus CYP450 basic in that process is CYP 2С19.

Key words: gidazepam, inductor, inhibitor, excretion, P-450 cytochrome.

REFERENCES

  1. SavchenkoMA. Isolation of gidazepam and its metabolites by solid-phase extraction.Pharmaceutical journal.2016; 2: 43–47.URL: https://doi.org/10.32352/0367-3057.2.16.02 (in Ukrainian).
  2. Chubenko AV, Savchenko MA.Development and validation of the method for determining hydazepam in biological material by chromatography-mass spectrometry.Vestn.Kazakh Nationalhoney.Univ.2015; 2: 504–507.
  3. Kolyvanov GB. Pharmacokinetic assessment of tablet dosage forms of hydazepam prepared by various technologies. Experimental and clinical pharmacology. 2004; Volume 67, No. 2: 63–66.
  4. Golovenko NYa, Venerable EV.Pharmacological and toxicological characteristics of hydazepam and its metabolites.Contemporary problems of toxicology.2007; 4: 39–41.
  5. Synthesis of Benzodiazepines Through Ring Opening/Ring Closure of Benzimidazole Salts/ Sheng Tao, Dr. Qingqing Bu, Qianqian Shi, Prof. Dr. Donghui Wei. Chemistry – А European Journal. 2020; 26. № 15: 3252–3258. https://doi.org/10.1002/chem.201905828.
  6. Benzodiazepines: Uses, Dangers, and Clinical Considerations/ Edinoff A.N., Nix C.A., Hollier J., et al. Neurol Int. 2021; № 13(4): 594–607. doi: 10.3390/neurolint13040059.
  7. Golovenko NYa, Kravchenko IA.Biochemical pharmacology of prodrugs.Odessa: Ecology, 2007; 352.
  8. Testa B, Kraemer SD. The biochemistry of drug metabolism – An introduction. Part 2. Redox reactions and their enzymes. Chem. Biodivers. 2007; Vol. 4, № 3: 257–405. PMID: 17372942 DOI: 10.1002/cbdv.200790032.
  9. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008; № 64(12): 1147–1161. doi: 10.1007/s00228-008-0553-z.
  10. Guengerich FP. Mechanisms of Cytochrome P450-Catalyzed Oxidations. ACS Catal. 2018; № 8(12):10964–10976. doi: 10.1021/acscatal.8b03401.
  11. Golovenko NYa. Physical and chemical pharmacology. Odessa: Astroprint; 2004. pp. 105–112.
View article PDF